Viewing Study NCT00412412


Ignite Creation Date: 2025-12-26 @ 11:08 AM
Ignite Modification Date: 2025-12-26 @ 11:08 AM
Study NCT ID: NCT00412412
Status: COMPLETED
Last Update Posted: 2012-06-08
First Post: 2006-12-15
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study
Sponsor: Biogen
Organization:

Study Overview

Official Title: A Ph1 Open-Label,Dose-Escalation,Safety,PK & PD Study of CNF2024 as a Single-Agent Treatment in Subjects w/HER2- Adv Breast Cancer or in Combo w/Trastuzumab in Subjects w/HER2+ Advanced Breast Cancer
Status: COMPLETED
Status Verified Date: 2011-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this clinical research study is to study the drug CNF2024 as a single agent or in combination with trastuzumab in patients with advanced breast cancer and to:

* find the highest dose of the drug CNF2024 as a single agent or in combination with trastuzumab that can be given safely
* measure levels of CNF2024 as a single agent or in combination with trastuzumab in blood
* determine if CNF2024 as a single agent or in combination with trastuzumab can stop breast cancer cells from growing
Detailed Description: A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CNF2024 as a Single-Agent Treatment in Subjects with HER2- Advanced Breast Cancer or in Combination with Trastuzumab in Subjects with HER2+ Advanced Breast Cancer

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: